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Background: Lenvatinib has been approved by regulatory agencies in Japan, the 
United States, and the European Union for treatment of radioiodine-refractory differen-
tiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease 
that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest 
lethality. Effective therapy for ATC is an unmet need.
Patients and methods: This phase 2, single-arm, open-label study in patients with 
thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted 
from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until 
disease progression or development of unacceptable toxicity. The primary endpoint 
was safety, and the secondary endpoint was efficacy, as assessed by progression-free 
survival (PFS), overall survival (OS), and objective response rate.
results: At data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 
treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased 
appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). 
Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this 
TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% 
confidence interval (CI): 1.7–12.9], the median OS was 10.6 months (95% CI: 3.8–19.8), 
and the objective response rate was 24%.
conclusion: In this study, lenvatinib demonstrated manageable toxicities with dose 
adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib 
warrants further investigation in ATC.
clinicalTrials.gov: NCT01728623.
Keywords: lenvatinib, anaplastic thyroid cancer, tyrosine kinase inhibitor, phase 2, clinical trial
inTrODUcTiOn
Thyroid cancer is a clinically diverse disease that can be classified into differentiated, medullary, 
and anaplastic thyroid cancer (ATC) subtypes. ATC is an undifferentiated tumor from the fol-
licular epithelium and typically presents with a rapidly enlarging mass as well as dysphagia, neck 
pain, vocal cord paralysis, and dyspnea (1). Nearly half of all patients with ATC have metastatic 
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disease at initial diagnosis (1). According to the American Joint 
Committee on Cancer, all patients diagnosed with ATC are 
classified with stage IV disease (2, 3). Although the incidence 
is rare among thyroid cancers (1–2%), ATC represents an unmet 
medical need and is difficult to treat, with an associated mortality 
rate over 90% (4).
Current therapies for ATC have limited efficacy. Historically, 
doxorubicin has been considered the most effective treatment, 
with a response rate of ~20% (5, 6). When combined with other 
chemotherapies, a higher response rate (50%) can be achieved, 
but the duration of response is often short (2–5 months) (7, 8). 
A phase 2 trial of paclitaxel in patients with ATC reported an 
overall response rate (ORR) of 53%; another trial of carboplatin 
and paclitaxel in combination with fosbretabulin reported 
a non-significant increase in overall survival (OS) (9, 10). 
Combination therapies have also been associated with substan-
tial toxicities, including leukocytopenia, neutropenia, anemia, 
diarrhea, and vomiting (11).
A total of four multikinase agents are approved for thyroid 
cancer treatment: cabozantinib (12) and vandetanib (13) for 
medullary thyroid cancer and sorafenib (14) and lenvatinib for 
radioiodine-refractory differentiated thyroid cancer (RR-DTC) 
(15). However, knowledge of their efficacy in ATC is limited. 
Lenvatinib is a multikinase inhibitor that targets the vascular 
endothelial growth factor receptor 1–3, fibroblast growth factor 
receptor 1–4, platelet-derived growth factor receptor-alpha, and 
RET and KIT proto-oncogenes (16–19). In a preclinical study, 
lenvatinib demonstrated antitumor activity in mouse ATC xeno-
graft models (19).
Lenvatinib was approved for the treatment of RR-DTC based 
on results from the phase 3 Study of (E7080) Lenvatinib in 
Differentiated Cancer of the Thyroid (SELECT) trial (15, 20). In 
that study, lenvatinib prolonged progression-free survival (PFS) 
versus placebo [median PFS 18.3 versus 3.6 months; hazard ratio: 
0.21, 99% confidence interval (CI): 0.14–0.31; P < 0.001] (15). In 
a separate open-label phase 2 study of lenvatinib in patients with 
advanced medullary thyroid cancer, the ORR was 36% (95% CI: 
24–49%) (21).
This phase 2 study examines the safety and efficacy of 
lenvatinib in advanced thyroid cancer, including ATC. Although 
efficacy was not a primary objective, we highlight the efficacy 
outcome of patients with ATC in this report because encouraging 
preliminary evidence of antitumor activity was observed in this 
first trial of lenvatinib treatment for this disease.
PaTienTs anD MeThODs
Patients
Eligible patients were aged ≥20 years, had an Eastern Cooperative 
Oncology Group performance status of ≤2, systolic blood pres-
sure ≤140  mmHg, diastolic blood pressure ≤90  mmHg and 
had histologically confirmed diagnosis of any of the specified 
advanced thyroid cancer subtypes (anaplastic, radioiodine-
refractory differentiated, or medullary). Patients with ATC must 
have had evaluable target lesions per the Response Evaluation 
Criteria in Solid Tumors version 1.1, agreed to hospitalization in 
cycle 1, and were expected to live for ≥8 weeks after the first dose 
of study drug. Tumor samples from these patients were subjected 
to independent pathological review, where possible.
Exclusion criteria included concomitant brain metastases 
(unless previously treated and clinically stable for ≥1  month 
prior to screening), bleeding or thrombotic disorders, use of 
anticoagulants (e.g., warfarin), and proteinuria (urine protein 
levels of ≥1 g/24 h).
study Oversight
This study was sponsored by Eisai Co., Ltd., designed according 
to the Guidelines for Clinical Evaluation of Anticancer Drugs 
in Japan and conducted in accordance with the Declaration of 
Helsinki and local laws. All patients provided written infor-
med consent.
The study and protocol were approved by the Institutional 
Review Board of each medical institution (National Cancer Center 
Hospital East, Kashiwa, Japan; The Cancer Institute Hospital of 
Japanese Foundation for Cancer Research, Tokyo, Japan; and the 
Kobe University Hospital, Kobe, Japan). The study is registered at 
http://clinicaltrials.gov (NCT01728623).
Statistical analyses were performed by Eisai Co., Ltd., and 
Takumi Information Technology Inc., statisticians.
study Design
This was a single-arm, open-label, multicenter, phase 2 study 
to evaluate the safety and efficacy of lenvatinib in patients with 
advanced thyroid cancer at three study sites in Japan from 
3 September 2012 to 9 July 2015. Patients received treatment until 
progressive disease according to Response Evaluation Criteria in 
Solid Tumors version 1.1 or development of unacceptable toxic-
ity. Lenvatinib was administered orally at 24 mg once daily on a 
28-day continuous cycle. For patients with ATC, tumor assess-
ments were performed at 4, 8, 12, and 16 weeks after the first dose, 
and every 8  weeks thereafter. Tumor responses were evaluated 
based on investigator assessment.
Because of historically poor OS, patients with ATC were fol-
lowed every 4 weeks after treatment discontinuation. Enrollment 
for this study continued until lenvatinib was approved for unre-
sectable thyroid cancer in Japan, and after approval continued 
as a post-marketing study until lenvatinib was commercially 
available at each site. The protocol was amended to include 
the post-marketing study, but the endpoints and analysis were 
not changed.
safety and efficacy analyses
The primary endpoint was the safety of lenvatinib in patients 
with advanced thyroid cancer, including adverse events (AEs), 
clinical laboratory results (including urinalysis, hematology, and 
blood chemistry), vital signs, weight, electrocardiography, and 
Eastern Cooperative Oncology Group performance status. The 
assessment of AEs were completed using the Medical Dictionary 
for Regulatory Activities, and AEs were graded using Common 
Terminology Criteria for AEs version 4.0.
The secondary endpoints included: PFS (defined as time from 
the date of first dose to first documentation of disease progression 
FigUre 1 | Patient disposition and reason for discontinuation from study treatment.
TaBle 1 | Baseline patient characteristics.
category n = 17
Median age, years 65.0
Male sex, n (%) 6 (35)
Median weight, kg 54.2
Range 39.9–85.3
Eastern Cooperative Oncology Group performance status, n (%)
0 5 (29)
1 10 (59)
2 2 (12)
Stage at diagnosis, n (%)
IVA 4 (24)
IVB 5 (29)
IVC 6 (35)
Unknown 2 (12)
Median baseline lesion diameter, mm 52
Previous therapy, n (%)
Anticancer surgical therapy 14 (82)
Anticancer chemotherapy 7 (41)
Vascular endothelial growth factor therapy 0
Radiotherapy 9 (53)
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as determined by investigator assessment, or death, whichever 
occurred first), OS (defined as time from the date of first dose to 
the date of death from any cause), ORR (defined as the proportion 
of patients with a complete or partial response), disease control 
rate (defined as the proportion of patients with complete or 
partial response, or stable disease, where stable disease must last 
≥3 weeks for ATC), and clinical benefit rate [defined as the pro-
portion of patients with complete or partial response, or durable 
stable disease (stable disease lasting ≥11 weeks for ATC)].
statistical analysis
Statistical analyses were performed using Statistical Analysis 
System (version 9.2 or later). A sample size of ≥16 was planned, 
which was estimated to have a probability of >0.8 (or 80%) 
to detect AEs with a frequency of ≥10%. No adjustments for 
covariates and no statistical comparisons were planned. Efficacy 
analyses of PFS and OS were summarized by the Kaplan–Meier 
method using median time with 95% CI.
resUlTs
Patients
Of the 60 patients screened, nine failed to meet inclusion or met 
exclusion criteria and 51 were enrolled [Figure  1 (CONSORT 
diagram)]. There were 17 patients with ATC and results for this 
patient group are reported here. Tumor samples were available 
for 10 of these patients and all were retrospectively confirmed to 
be anaplastic by an independent pathologist. All 17 patients with 
ATC were included in efficacy and safety analyses. At data cutoff, 
four (17%) were on treatment, 12 (46%) discontinued because 
of disease progression, and one (6%) discontinued because of 
an AE that was deemed unrelated to lenvatinib treatment by the 
investigator (suicide attempt).
Patient baseline characteristics are summarized in Table 1. 
All patients were Asian (Japanese) with baseline Eastern 
Cooperative Oncology Group performance status of 0 or 1, 
except for two patients with a score of 2. The majority of patients 
were females (65%) and the median age was 65  years. Most 
patients (82%) had previous thyroid cancer surgery. Of these 
patients, seven (41%) had received previous chemotherapy, nine 
(53%) had received prior external radiotherapy, and two (12%) 
had not received any prior treatment.
safety
The median duration of lenvatinib treatment was 5.5  months 
(range: 0.7–33.1). All patients experienced ≥1 treatment- 
FigUre 2 | Percentage change from baseline in summed tumor 
diameter.
TaBle 2 | Treatment-emergent adverse events (aes) (≥20% of patients in 
the anaplastic thyroid cancer subgroup).
Treatment-emergent aes, n (%) n = 17
any grade grade 3 grade 4
Decreased appetite 14 (82) 3 (18) 0
Hypertension 14 (82) 5 (29) 0
Fatigue 10 (59) 1 (6) 0
Nausea 10 (59) 0 (0) 0
Proteinuria 10 (59) 1 (6) 0
Palmar-plantar erythrodysesthesia syndrome 8 (47) 0 0
Stomatitis 8 (47) 0 0
Constipation 7 (41) 0 0
Decreased weight 7 (41) 0 0
Dysphonia 7 (41) 0 0
Vomiting 6 (35) 0 0
Diarrhea 5 (29) 0 0
Headache 5 (29) 0 0
Increased alanine aminotransferase 5 (29) 0 0
Increased aspartate aminotransferase 5 (29) 0 0
Thrombocytopenia 5 (29) 2 (12) 1 (6)
Peripheral edema 5 (29) 0 0
Arthralgia 4 (24) 0 0
Dehydration 4 (24) 0 0
Epistaxis 4 (24) 0 0
Hypothyroidism 4 (24) 0 0
Malignant neoplasm progression 4 (24) 1 (6) 0
Productive cough 4 (24) 0 0
Pyrexia 4 (24) 0 0
TaBle 3 | efficacy measures.
Outcome n = 17
Progression-free survival
Median [95% confidence interval (CI)], months 7.4 (1.7–12.9)
Overall survival
Median (95% CI), months 10.6 (3.8–19.8)
Best overall response, n (%)
Complete response 0
Partial response 4 (24)
Stable diseasea 12 (71)
Progressive disease 1 (6)
Not evaluable 0
Objective response rate, n (%)b 4 (24)
Disease control rate, n (%)b 16 (94)
Clinical benefit rate, n (%)c 12 (71)
aStable disease is defined as lasting ≥3 weeks.
bPercentages are based on the patients categorized as evaluable for each parameter. 
The disease control rate was calculated as complete response plus partial response 
plus stable disease.
cThe clinical benefit rate was calculated as complete response plus partial response 
plus durable stable disease (defined as stable disease lasting ≥11 weeks).
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emergent adverse event (TEAE), of which ≥1 was deemed 
treatment-related by the investigator.
Grade 3 TEAE occurred in 13 (77%) patients and grade 4 
TEAE occurred in only one (6%) patient. A summary of common 
TEAE is shown in Table 2. The most common grade 3 or 4 TEAE 
were hypertension (n = 5; 29%), decreased appetite (n = 3; 18%), 
and thrombocytopenia (n = 3; 18%). Serious AEs were reported 
in 13 patients. There were four fatal serious AEs that occurred 
within 30 days of the last dose of lenvatinib for this study, three 
of which occurred in patients with ATC. These three patients 
died of primary disease progression. All deaths were reported as 
unrelated to lenvatinib.
Fifteen (88%) patients required dose reductions and 11 (65%) 
required dose interruptions because of TEAE. The median time 
to dose reduction was 0.7  months (range: 0.2–1.4). The most 
frequent TEAE leading to dose reduction were decreased appetite 
(n = 6; 35%), thrombocytopenia (n = 3; 18%), headache (n = 3; 
18%), fatigue (n = 3; 18%), hypertension (n = 2; 12%), nausea 
(n = 2; 12%), and palmar-plantar erythrodysesthesia syndrome 
(n = 2; 12%).
efficacy
Efficacy outcomes are summarized in Table  3. At data cutoff, 
eight (47%) patients had received >6  months of lenvatinib 
treatment. The median PFS was 7.4 months (95% CI: 1.7–12.9) 
and the median OS was 10.6  months (95% CI: 3.8–19.8). The 
ORR was 24% and there were four (24%) patients with partial 
response, 12 (71%) patients with stable disease, and one (6%) 
patient with progressive disease. Of the four patients with partial 
responses, four  (100%) had previous thyroid cancer surgery, 
two (50%) had received previous chemotherapy, and two (50%) 
had prior external radiotherapy. The disease control rate was 94% 
and clinical benefit was achieved by 12 (71%) patients.
Clinical activity was observed in the majority of patients 
(Figure 2). Patients with ATC demonstrated a durable response to 
lenvatinib therapy throughout the course of the study (Figure 3). 
Further, the observed tumor shrinkage in these patients was 
continuous throughout treatment (Figure  4). These results are 
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illustrated by computed tomography scans of a representative 
patient with ATC, which revealed remarkable tumor reduction 
at 24 and 72 weeks post-lenvatinib treatment compared with a 
baseline scan (Figure 5).
DiscUssiOn
In this phase 2 study, lenvatinib demonstrated a manageable 
safety profile and meaningful antitumor activity in patients with 
ATC. The safety profile reported here was comparable to that 
observed in the phase 2 trial of lenvatinib in medullary thyroid 
cancer, the phase 3 SELECT trial of lenvatinib in RR-DTC (15, 
21), and the Japanese subgroup analysis of the SELECT trial (22). 
Fatigue, decreased appetite, proteinuria, and hypertension were 
among the most frequent AEs observed, which are known class 
effects of vascular endothelial growth factor-targeted treatments 
(23). Toxicities were effectively managed with dose interruptions 
and reductions, as demonstrated by having only one patient 
FigUre 3 | Time to response and durability of response for patients with anaplastic thyroid cancer treated with lenvatinib.
FigUre 4 | Percentage change in tumor size from baseline with duration of lenvatinib treatment in patients with anaplastic thyroid cancer.
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discontinue treatment because of an AE, which was considered 
unrelated to lenvatinib.
Responses were observed in all subtypes studied, and most 
patients experienced tumor shrinkage. We especially note the 
encouraging responses in patients with ATC, an aggressive 
form of thyroid cancer with no effective treatment options. This 
study and the SELECT trial (15) supported regulatory approval 
of  lenvatinib for unresectable thyroid cancer in Japan, and 
 lenvatinib is now commercially available there for the treatment 
of ATC (24).
As lenvatinib demonstrated striking efficacy in RR-DTC 
(15), we hypothesized that the ATC subtype may be sensitive to 
lenvatinib based on evidence that ATC tumors evolved from a 
background of differentiated thyroid cancer (25). Preclinical 
studies have also shown that lenvatinib reduced tumor growth in 
human ATC xenograft mouse models (19). The high vascularity 
of ATC tumors may also make them more responsive to angio-
genesis inhibition by lenvatinib (26).
The ORR in patients with ATC on lenvatinib was noteworthy, 
with four (24%) patients achieving a partial response, 12 (71%) 
achieving stable disease, and eight (47%) with durable stable 
disease. In the context of other investigative or approved agents 
for the treatment of ATC, which have shown response durations 
from 2 to 27 months, lenvatinib demonstrated durable response 
and disease stabilization throughout the course of the study (8, 
27). Median OS in patients with ATC who received lenvatinib 
was 10.6  months, a particularly important finding given that 
previous studies have reported median OS of <8  months with 
the use of cytotoxic agents (4, 28, 29). AEs previously reported for 
paclitaxel included grade 1 stomatitis, alopecia, nausea, diarrhea, 
and fatigue, grade 2 nausea, gastritis, fever and netropenia, and 
grades 2−3 neuropathy (9). Doxorubicin is the only approved 
agent for ATC. Toxicities reported with doxorubicin treatment 
for advanced thyroid cancer included vomiting and hematologic 
toxicity (6). Because of the risk of developing cardiotoxicity 
with increasing total cumulative doxorubicin doses in excess of 
400 mg/m2, prolonged doxorubicin treatment is problematic (30).
Although there were no bleeding events in the current study, 
post-marketing surveillance in Japan recently reported some 
cases of carotid artery and tumor hemorrhage due to rapid 
tumor shrinkage in patients with ATC treated with lenvatinib. 
This is further evidence of the antitumor activity of lenvatinib in 
patients with ATC, although careful administration is especially 
warranted for patients with tumor invasion of the carotid arteries.
This study has several limitations. First, it is a non-randomized 
study with a relatively small patient population. Second, there was 
no biomarker evaluation of tumor samples. Finally, the results for 
the ATC subgroup represent only one cohort of the study that was 
not designed to evaluate efficacy of lenvatinib for this subtype as 
a primary endpoint. In addition, association of biomarkers with 
efficacy of lenvatinib in ATC was not evaluated in this study, but 
this will be examined as an exploratory endpoint in ongoing 
phase 2 trials of lenvatinib in patients with ATC (NCT02657369, 
NCT02726503). Despite these limitations, the encouraging 
results observed in this study indicate potentially important 
improvements in the treatment of advanced thyroid cancer.
In conclusion, lenvatinib therapy demonstrated manageable 
toxicities, with meaningful and promising antitumor activity 
in patients with ATC. The results warrant further investigation 
into the clinical value of lenvatinib for this rare and aggres-
sive malignancy.
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